On October 6, 2025, Maze Therapeutics, Inc. appointed Hervé Hoppenot as the Chairman of the Board, succeeding Dr. Charles Homcy. Hoppenot will receive compensation based on the company's policy and has been granted an option to purchase 36,000 shares.